Attorneys See Uncertainty in FDA's Implementation of Biosimilar Approvals, Life Sciences Law & Industry Report
Friday, May 28, 2010
Morgan Lewis partner Kathleen Sanzo discusses the use of traditional biologics license application (BLA) versus the new biosimilars pathway provided for in the healthcare reform law at the May 20 Washington Legal Foundation media briefing.